P2RX7

Across TCGA pan-cancer cohorts, P2RX7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated P2RX7 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher P2RX7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated P2RX7 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

GBM, CCRCC, and LSCC are the cancer types where P2RX7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.594	0.878	.018	6	view →
CCRCC	DFS	Median	III,IV	0.985	0.252	.042	2	view →
LSCC	OS	Quartile	III,IV	0.958	0.555	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

P2RX7–GBM (OS)

Open the GBM breakdown →